All Updates

All Updates

icon
Filter
Product updates
Parsley Health launches gastrointestinal care program for employees
Preventive Healthcare
Oct 9, 2023
This week:
Product updates
Hexagon unveils Advanced Compensation for metal 3D printing
Additive Manufacturing
Yesterday
Funding
Eden AI raises EUR 3 million in seed funding to accelerate product development
Generative AI Infrastructure
Nov 21, 2024
M&A
Wiz acquires Dazz to expand cloud security remediation capabilities
Next-gen Cybersecurity
Nov 21, 2024
Partnerships
Immutable partners with Altura to enhance Web3 game development and marketplace solutions
Web3 Ecosystem
Nov 21, 2024
Funding
OneCell Diagnostics raises USD 16 million in Series A funding to enhance cancer diagnostics
Precision Medicine
Nov 21, 2024
Partnerships
BioLineRx and Ayrmid partner to license and commercialize APHEXDA across multiple indications
Precision Medicine
Nov 21, 2024
Product updates
SOPHiA GENETICS announces global launch of MSK-IMPACT powered with SOPHiA DDM
Precision Medicine
Nov 21, 2024
Product updates
Biofidelity launches Aspyre Clinical Test for lung cancer detection
Precision Medicine
Nov 21, 2024
Partnerships
Spendesk partners with Adyen to enhance SMB spend management with banking-as-a-service solution
Business Expense Management
Nov 21, 2024
M&A
Mews acquires Swedish RMS provider Atomize to enhance Hospitality Cloud platform
Travel Tech
Nov 21, 2024
Preventive Healthcare

Preventive Healthcare

Oct 9, 2023

Parsley Health launches gastrointestinal care program for employees

Product updates

  • Parsley Health, a direct primary care provider, has launched a gastrointestinal (GI) program for self-insured employers and plan sponsors across the US. The program aims to address common digestive issues and their comorbidities, with the goal of lowering healthcare costs for employers.

  • The gastrointestinal program offered by the company treats conditions such as irritable bowel syndrome, small intestinal bacterial overgrowth, gut microbiome imbalances, and Crohn's disease. It combines personalized, tech-enabled, virtual care with root cause medicine and conventional approaches. The company claims this approach has been shown to improve symptoms for 88% of GI patients, reduce medication use for 26% of patients, and eliminate medications for 11% of patients within 15 months.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.